77877-20-4

Basic information

• Product Name: 2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)-
• Synonyms: 2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R-cis)-;(4R,5S)-4-Methyl-5-phenyl-3-propionyl-2-oxazolidinone
• CAS NO: 77877-20-4
• Molecular Formula: C₁₃H₁₅NO₃
• Molecular Weight: 233.2631
• Product Categories: Peptide
• Mol File: 77877-20-4.mol
• Article Data: 45

Chemical Properties

• Boiling Point: 394.4°C at 760 mmHg
• Flash Point: 192.3°C
• Appearance: /
• Density: 1.161 g/mL at 20 °C(lit.)
• Vapor Pressure: 1.98E-06mmHg at 25°C
• Refractive Index: 1.535
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)-(77877-20-4)
• EPA Substance Registry System: 2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)-(77877-20-4)

Safety Data

• Safety Statements: 23-24/25
• WGK Germany: 3
• F: 10
• Hazardous Substances Data: 77877-20-4(Hazardous Substances Data)

Usage

Description

2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)is a complex organic compound characterized by its unique molecular structure, which features an oxazolidinone ring, a methyl group, a phenyl group, and a propionyl group. 2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)is known for its potential applications in various fields due to its chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)is used as a reactant in the synthesis of Lactimidomycin, a potent translation and cell migration inhibitor. This application is significant because Lactimidomycin has shown promise in the development of new therapeutic strategies for various diseases, including cancer and other conditions characterized by abnormal cell migration and proliferation.
In the synthesis of Lactimidomycin, the compound (4R,5S)-4-Methyl-5-phenyl-3-propionyl-2-oxazolidinone serves as a key building block, contributing to the overall structure and biological activity of the final product. Its unique properties and reactivity make it an essential component in the development of this potent inhibitor, highlighting its importance in the pharmaceutical industry.

InChI:InChI=1/C13H15NO3/c1-3-11(15)14-9(2)12(17-13(14)16)10-7-5-4-6-8-10/h4-9,12H,3H2,1-2H3/t9-,12-/m1/s1

Upstream product

• 77943-39-6 4-methyl-5-phenyloxazolidin-2-one 
• 123-62-6 propionic acid anhydride 
• 492-39-7 (1S,2S)-2-amino-1-phenylpropanol 
• 4122-52-5 1-(1H-imidazol-1-yl)propan-1-one 
• 16251-45-9 (4S,5R)-4-methyl-5-phenyl-oxazolidin-2-one 
• 492-41-1 (1R,2S)-norephedrine 
• 802294-64-0 propionic acid 
• 79-03-8 propionyl chloride 
• 54418-69-8 4-methyl-5-phenyl-2-oxazolidinone 
• 116782-32-2 (1S,2R)-1-phenyl-2-<(ethoxycarbonyl)amino>propanol 
• 37577-28-9 (1S,2R)-(+)-norphedrine 
• 40626-29-7 Acutrim 
• 598-26-5 dimethylketene 
• 24423-87-8 3,4-dihydro-isoquinoline 2-oxide 

Downstream Products

• 77877-24-8 (4R,5S)-[(2R,3S)-3-hydroxy-2-methylheptanoyl]-4-methyl-5-phenyl-2-oxazolidinone 
• 80697-95-6 (4R,5S)-4-methyl-3-((S)-2-methylpent-4-enoyl)-5-phenyloxazolidin-2-one 
• 129985-93-9 <3(2R,3S,4E),4R,5S>-3-(3-hydroxy-2-methyl-1-oxo-4-heptenyl)-4-methyl-5-phenyl-2-oxazolidinone 
• 121444-36-8 (4R,5S)-4-methyl-3-<(2R)-2-methyl-4-heptynoyl>-5-phenyl-2-oxazolidinone 
• 121444-33-5 (4R,5S)-4-methyl-3-<(2S)-2-methyl-4-heptynoyl>-5-phenyl-2-oxazolidinone 
• 115820-61-6 (4R,5S)-3-[(2R,3R)-3-Hydroxy-3-(2-methoxy-3-nitro-phenyl)-2-methyl-propionyl]-4-methyl-5-phenyl-oxazolidin-2-one 
• 115889-52-6 (4R,5S)-3-[(2S,3S)-3-Hydroxy-3-(2-methoxy-3-nitro-phenyl)-2-methyl-propionyl]-4-methyl-5-phenyl-oxazolidin-2-one 
• 115889-51-5 (4R,5S)-3-[(2S,3R)-3-Hydroxy-3-(2-methoxy-3-nitro-phenyl)-2-methyl-propionyl]-4-methyl-5-phenyl-oxazolidin-2-one 
• 79563-31-8 (4R,5S)-4-methyl-3-[2(R)-methyl-1-oxobutyl]-5-phenyloxazolidin-2-one 
• 79563-30-7 (4R,5S)-4-Methyl-3-[(S)-2-methylbutyryl]-5-phenyloxazolidin-2-one 
• 115820-57-0 (4R,5S)-3-[(2R,3R)-3-Hydroxy-3-(2-methoxy-phenyl)-2-methyl-propionyl]-4-methyl-5-phenyl-oxazolidin-2-one 
• 160423-36-9 (4R,5S)-3-((E)-(2R,3R)-5-tert-Butylsulfanyl-3-hydroxy-2-methyl-pent-4-enoyl)-4-methyl-5-phenyl-oxazolidin-2-one 
• 158830-95-6 (+)-(4R,5S)-3-<(2R,3S)-(E)-6-(2-Bromo-1-cyclohexanylidene)-5,5-(ethylenedioxy)-3-hydroxy-2-methylhexanoyl>-4-methyl-5-phenyl-2-oxazolidinone 
• 159692-46-3 (4R,5S)-3-[(2R,3S,4R)-3-Hydroxy-4-((4R,6S)-6-{(1R,2S)-2-methoxy-3-[(2S,4S)-2-(4-methoxy-phenyl)-[1,3]dioxan-4-yl]-1-methyl-propyl}-2,2-dimethyl-[1,3]dioxan-4-yl)-2-methyl-pentanoyl]-4-methyl-5-phenyl-oxazolidin-2-one 

Relevant articles and documents

NOVEL CONNECTED BODY AND USE THEREOF IN SPECIFIC CONJUGATION BETWEEN BIOMOLECULE AND DRUG

PROBLEM TO BE SOLVED: To provide: a method for producing a connected body; a method for using the connected body in the production of a uniform conjugate; and a method for applying the conjugate in the treatment of cancer, infectious diseases, and autoimmune diseases. SOLUTION: A novel connected body is provided that includes a 2,3-di-substituted succinic acid group or a 2-mono-substituted or 2,3-di-substituted fumaric acid or maleic acid (trans (E)- or cis (Z)-butenedioic acid) group for conjugating 2 or more compounds/cytotoxic agents per connected body with a cell-binding molecule by specifically bridge-linking to a pair of thiol on the cell-binding molecule. The connected body is exemplified by the following general formula. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

EFFICIENT PREPARATION OF DOLASTATIN AND AURISTATIN ANALOGS THROUGH A COMMON INTERMEDIATE

Methods for making a dolastatin, auristatin or related compounds comprising the steps of providing a universal dolastatin core of Formula (I) reacting the C-terminal carboxylic acid group with an amine (A) to form an amide bond and reacting the N-terminal amine with a carboxylic acid (CA) to form an amide bond, wherein the steps can be performed in either order. Also provided are an isolated salt of the universal dolastatin core for use in preparation of dolastatins, auristatins and related compounds. Also provided are a number of intermediates and process steps which are useful for the preparation of high purity dolastatin core and high purity dolastatin and auristatin compounds.

CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE

What provided is the conjugation of cytotoxic to a cell-binding molecule with a bis-linker(dual-linker) as shown in Formula (I). It provides bis-linkage methods of making a conjugate of a cytotoxic drug molecule to a cell-binding agent in a specific manner. It also relates to application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease.